CYNORA Introduces Fluorescent Blue Emitter That Gives OLED Devices a Substantial Efficiency Boost
CYNORA today debuted its first commercial product, a fluorescent blue emitter that promises to significantly improve the efficiency of Organic Light Emitting Diode (OLED) displays used in mobile phones, laptops, TVs, and other applications. The company is an emerging OLED materials leader. The product, known as the cyBlueBooster™, employs an advanced molecular design and is >15 percent more efficient than comparative emitters. It can be easily integrated into existing OLED stacks and is available in multiple shades of blue for application customization. The product aims to help display manufacturers immediately harness untapped efficiencies in the emission layer of their OLED devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005067/en/
cyBlueBooster - CYNORA's Fluorescent Blue Emitter in OLED device (Photo: Dr. Harald Flügge, cynora GmbH)
The launch marks CYNORA’s transition from cutting-edge research and development to commercialization. The new product is the first on a technology roadmap that will later include green and blue emitters based on the company’s proprietary and differentiated TADF materials platform.
The OLED market continues to grow with the technology driving an array of flexible, foldable and ultra-thin displays. To enable the novel form factors and achieve superior color points, low power consumption is a central imperative. Yet, while OLED technology is well in the mainstream, the OLED devices have still to reach peak efficiency. The emission layers determine the overall performance of the OLED stack and exert a strong influence on power consumption. Blue is the least efficient emitter. Consequently, the industry is focusing intensely on finding new ways to improve efficiency. Also, with next-generation displays like QD OLEDs using blue emitters only, the need for ultra-high-efficiency options is even more urgent.
CYNORA developed the cyBlueBooster to address the high-efficiency imperative. Engineered using proprietary simulation techniques, the product delivers >15 percent higher efficiency over comparative solutions, while also improving the color point. It has a narrow emission spectrum (<30nm full-width at half maximum) which reduces harmful UV light and makes the viewing experience easier on the eye. The product can be seamlessly integrated into existing OLED devices with only minor adjustments to the stack. Depending on the application, customers can select a particular shade of blue to optimize their stack and further differentiate their OLED products.
CYNORA CEO, Adam Kablanian, called the product a compelling alternative option for current-and-future-generation OLED displays. “We built the product in collaboration with OLED ecosystem partners, not just to drive better performance and efficiency advantages, but also with simplicity of integration in mind. It’s the result of extensive materials research by our technologists and their keen knowledge of OLED efficiency gaps. We’re pleased to mark this first commercial milestone. The innovation continues as we work to refine our next products.”
For information on the product, please visit https://www.cynora.com/technology/cyblueboostertm/
For information on CYNORA, please visit http://www.cynora.com
cyBlueBooster is a trademark of cynora GmbH
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005067/en/
Contact information
cynora GmbH
Nicole Rauenbühler
m: +49 7251 919 670
email: press@cynora.com
Agency
Jane Evans-Ryan
Genuity Communications
m: +408-489-6391
email: jane@genuitypr.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom